AstraZeneca mulls €240bn mega-merger with Gilead Sciences

Pharma firm AstraZeneca is considering a merger with US peer Gilead Sciences to create a company with a market value of $240bn.

Britain’s AstraZeneca has been considering “the biggest pharmaceuticals deal in history”, says Max Nisen on Bloomberg: merging with US peer Gilead Sciences to create a company with a market value of $240bn. The aim would be to combine AstraZeneca’s “enviable” drug pipeline with Gilead’s profitable HIV drug business, which has given it a “steady cash flow” and “strong balance sheet”.

Any merger with Gilead would be a bad mistake, says Ben Marlow in The Daily Telegraph. Not only is there “overwhelming” evidence that most mega-mergers end up destroying value, but the ongoing travel restrictions also mean that this one could “take several years to be negotiated”. In any case, with AstraZeneca at the forefront of developing a coronavirus vaccine as well as various treatments for those already infected with the disease, it needs to “concentrate on the day job”. The last thing managers should be doing is “wasting time” with “desktop empire-building”.Tentative talks seem to have gone nowhere, says Nils Pratley in The Guardian. Still, the fact that the idea was even broached at all will unnerve shareholders “who thought the future for the next few years was mapped out and rosy”. 

With new cancer drug sales “soaring [and the]cardiovascular and respiratory divisions [ready] to deliver the next round of growth”, AstraZeneca’s CEO Pascal Soriot (pictured) should stick with his current strategy. Instead, he apparently dreams of “signing off in dreaded transformative style” with a deal that could prove “messy and political”.

Recommended

Think Tesla is a bubble? This might be the best way to bet on it bursting
Oil

Think Tesla is a bubble? This might be the best way to bet on it bursting

The huge rise in Tesla’s share price means that, by market value, it’s now the sixth-largest company in the US and and the world’s biggest car-maker. …
25 Jan 2021
Three clean energy stocks for your portfolio
Share tips

Three clean energy stocks for your portfolio

Professional investor Christian Roessing of the Pictet Clean Energy Fund highlights of his three favourite stocks at the forefront of the clean energy…
25 Jan 2021
The MoneyWeek Podcast: let's talk about bubbles
Stockmarkets

The MoneyWeek Podcast: let's talk about bubbles

Merryn and John talk about the many obvious signs of a bubble in certain assets, including tech stocks, TikTok, and stock-trading 12-year olds. It's c…
22 Jan 2021
Eternal growth: how to invest in the future of the drinks industry
Share tips

Eternal growth: how to invest in the future of the drinks industry

Humans have been dabbling in tasty beverages for millennia. Jonathan Compton assesses the key trends in the sector and recommends seven hard- and soft…
22 Jan 2021

Most Popular

The FTSE 100 is set for a makeover with an influx of new tech stocks
UK stockmarkets

The FTSE 100 is set for a makeover with an influx of new tech stocks

The FTSE 100 – the dullest index in the world – is about to reinvent itself as a host of new firms list on the market. The change is long overdue, say…
24 Jan 2021
Think Tesla is a bubble? This might be the best way to bet on it bursting
Oil

Think Tesla is a bubble? This might be the best way to bet on it bursting

The huge rise in Tesla’s share price means that, by market value, it’s now the sixth-largest company in the US and and the world’s biggest car-maker. …
25 Jan 2021
Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021